Latest Product Launch News

Cogstate Ltd has reported a strong FY25 with 22% revenue growth and a near doubling of profit before tax, declaring its first fully franked dividend and preparing to launch its inaugural AI-powered product in FY26.

Cogstate Limited has reported a landmark FY25 with revenue up 22% and net profit before tax nearly doubling, driven by a surge in clinical trials contracts and strategic innovation. The company also declared its maiden fully franked dividend and outlined ambitious growth plans including AI product launches and an expanding Medidata partnership.

GQG Partners reported a robust first half of 2025 with funds under management rising to US$172.4 billion and net revenue increasing 11%, driven by solid net inflows and capital appreciation. The firm also expanded its product suite, including launching an active ETF, while maintaining strong investment performance across strategies.

GQG Partners Inc. reported robust first-half 2025 results with revenue up 11% and net income rising 14.4%, alongside a new US ETF launch and a declared interim dividend.

Australian Vintage Ltd reported a modest 1% revenue decline in FY25 but significantly narrowed its net loss, setting the stage for a transformational FY26 driven by new CEO leadership and innovative product launches.

NRW Holdings delivered a robust FY25 performance, posting a 12.2% revenue increase to $3.27 billion and securing a strong $6.1 billion order book. The company’s FY26 outlook remains positive with expected revenue growth and improved earnings.

Codan Limited reported a robust FY25 with 22% revenue growth to $674.2 million and a 27% jump in net profit, driven by organic expansion and strategic acquisitions. The company’s communications and metal detection segments both posted solid gains, setting a confident tone for FY26.

Codan Limited reported a robust FY25 with revenue climbing 22% to $674.2 million and net profit rising 27%, driven by strong performances in its Communications and Metal Detection segments.

Telix Pharmaceuticals reported a robust 63% revenue increase in H1 2025, driven by commercial growth and strategic investments, while advancing key clinical trials and maintaining full-year guidance.

Bega Cheese Limited reported a robust FY2025 with a 23% rise in normalised EBITDA to $202 million, underpinned by branded growth and a turnaround in its bulk segment. Strategic manufacturing rationalisation and new product innovation set the stage for continued momentum.

Bega Cheese Limited reported a robust FY2025 with a 23% rise in normalised EBITDA, driven by strong branded product growth and a turnaround in its Bulk segment. The company forecasts further gains in FY2026 with new product launches and operational efficiencies.

Bega Cheese Limited reported a mixed FY2025 with statutory revenue edging up to $3.54 billion but a statutory loss after tax of $8.5 million, offset by a strong normalised profit and a 50% dividend increase. The company is advancing manufacturing rationalisation and sustainability initiatives while expanding internationally.